Anna Protopapas is Director of Mersana Therapeutics, Inc.. Currently has a direct ownership of 125,153 shares of MRSN, which is worth approximately $191,484. The most recent transaction as insider was on Jan 16, 2024, when has been sold 29,399 shares (Common Stock) at a price of $2.71 per share, resulting in proceeds of $79,671. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 125K
0% 3M change
85.15% 12M change
Total Value Held $191,484

Anna Protopapas Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 16 2024
SELL
Open market or private sale
$79,671 $2.71 p/Share
29,399 Reduced 19.02%
125,153 Common Stock
Jan 15 2024
BUY
Exercise of conversion of derivative security
-
38,958 Added 20.13%
154,552 Common Stock
Jan 14 2024
BUY
Exercise of conversion of derivative security
-
16,750 Added 12.66%
115,594 Common Stock
Jan 13 2024
BUY
Exercise of conversion of derivative security
-
31,250 Added 24.02%
98,844 Common Stock
Sep 11 2023
BUY
Grant, award, or other acquisition
-
16,643 Added 19.76%
67,594 Common Stock
Jan 17 2023
SELL
Open market or private sale
$99,566 $5.74 p/Share
17,346 Reduced 26.25%
48,733 Common Stock
Jan 15 2023
BUY
Exercise of conversion of derivative security
-
38,958 Added 37.09%
66,079 Common Stock
Jan 14 2023
BUY
Exercise of conversion of derivative security
-
16,750 Added 38.18%
27,121 Common Stock
May 20 2022
SELL
Bona fide gift
-
240,244 Reduced 95.86%
10,371 Common Stock
Jan 14 2022
BUY
Exercise of conversion of derivative security
-
38,958 Added 10.77%
322,878 Common Stock
Jul 19 2021
SELL
Open market or private sale
$263,250 $12.02 p/Share
21,901 Reduced 7.18%
282,978 Common Stock
Jul 16 2021
SELL
Open market or private sale
$249,936 $12.47 p/Share
20,043 Reduced 6.17%
304,879 Common Stock
Jul 15 2021
BUY
Exercise of conversion of derivative security
-
100,000 Added 23.53%
324,922 Common Stock
Jan 15 2021
SELL
Payment of exercise price or tax liability
$109,626 $21.09 p/Share
5,198 Reduced 2.26%
224,922 Common Stock
Jan 15 2021
BUY
Exercise of conversion of derivative security
-
17,709 Added 7.15%
230,120 Common Stock

Also insider at

DRNA
Dicerna Pharmaceuticals Inc
NUVL
Nuvalent, Inc. Healthcare
AP

Anna Protopapas

Director
Cambridge, MA

Track Institutional and Insider Activities on MRSN

Follow Mersana Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MRSN shares.

Notify only if

Insider Trading

Get notified when an Mersana Therapeutics, Inc. insider buys or sells MRSN shares.

Notify only if

News

Receive news related to Mersana Therapeutics, Inc.

Track Activities on MRSN